Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07216703 · ClinicalTrials.gov registry record · Phase 3

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

A Phase 3 study of Cervical Cancer, sponsored by Merck Sharp & Dohme.

Recruiting
Registry status
Phase 3
Development phase
1,023
Enrollment target
20
Study locations

NCT07216703: Recruiting Phase 3 study of Cervical Cancer, sponsored by Merck Sharp & Dohme.

NCT07216703 is a Phase 3 study of Cervical Cancer that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 1,023 participants, above the 563-participant average among 144 other Cervical Cancer trials with a reported enrollment target (82% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07216703, a Phase 3 study of Cervical Cancer, is actively recruiting participants, sponsored by Merck Sharp & Dohme.

RECRUITING
Registry status
Phase 3
Development phase
1,023 participants
Enrollment target
20
Study locations

Study Summary

Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumotecan (also called sac-TMT or MK-2870) along with pembrolizumab and bevacizumab treatments. Sac-TMT is an antibody drug conjugate, which is a type of medicine that attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of sac-TMT with pembrolizumab and bevacizumab, and if people tolerate them when given together, and * If people who receive sac-TMT and pembrolizumab, with or without bevacizumab, live longer overall or without their cancer getting worse as compared to those who receive standard treatment

Primary Outcome

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Conditions Studied

Cervical Cancer

Interventions

  • BIOLOGICAL Pembrolizumab
  • DRUG Cisplatin
  • DRUG Paclitaxel
  • BIOLOGICAL Bevacizumab
  • BIOLOGICAL Sacituzumab Tirumotecan

Study Locations (20)

Quebec

  • Centre Hospitalier de l'Université de Montréal ( Site 0616) - Montreal
  • McGill University Health Centre ( Site 0602) - Montreal
  • Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0611) - Québec

Santa Fe Province

  • Instituto de Oncologia de Rosario ( Site 0104) - Rosario
  • Hospital Provincial del Centenario ( Site 0106) - Rosario

Moravskoslezský kraj

  • Nemocnice AGEL Novy Jicin a.s. ( Site 1004) - Nový Jičín
  • Fakultni nemocnice Ostrava ( Site 1005) - Ostrava

Florida

  • Mount Sinai Comprehensive Cancer Center ( Site 6000) - Miami Beach

Louisiana

  • TRIALS 365 ( Site 6008) - Shreveport

Nevada

  • Women's Cancer Center of Nevada ( Site 6011) - Las Vegas

New York

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 6009) - New York

Tennessee

  • University of Tennessee Medical Center ( Site 6012) - Knoxville

Trial Details

FieldValue
Enrollment Target 1,023 participants
Start Date 2026-01-19
Est. Completion 2031-10-29
Phase Phase 3
Merck Sharp & Dohme

558 total trials

What NCT07216703 shows while recruiting

NCT07216703 is an interventional study that assigns participants to a tested intervention. Its 1,023 participants enrollment target places it among the larger protocols in the corpus, above the 563-participant average among 144 other Cervical Cancer trials with a reported enrollment target (82% higher).

The record links to 1 condition, with Cervical Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.

NCT07216703 names 20 study sites across 16 states, led by Quebec, Santa Fe Province, Moravskoslezský kraj.

Frequently Asked Questions

What is clinical trial NCT07216703 about?

NCT07216703 is a clinical study titled "A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)". Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumoteca...

What is the current status of trial NCT07216703?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,023 participants. The study started on 2026-01-19. Estimated completion is 2031-10-29.

What conditions does trial NCT07216703 study?

This clinical trial studies the following conditions: Cervical Cancer.

What interventions are being tested in trial NCT07216703?

The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Cisplatin (DRUG), Paclitaxel (DRUG), Bevacizumab (BIOLOGICAL), Sacituzumab Tirumotecan (BIOLOGICAL).

Who is sponsoring clinical trial NCT07216703?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07216703 being conducted?

This trial has 20 study locations across Florida, Louisiana, Nevada, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cervical Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07216703's enrollment target sits among peer trials

1,023 15th of 144 higher than 130 of 144 other Cervical Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cervical Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06888011 · 1,024 participants · NA

    iAmHealthy Clinical Practice Guideline (CPG)

  • NCT02200276 · 1,025 participants · NA

    Influenza Immunization in Adults Over Age 75

  • NCT02296450 · 1,025 participants

    Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL Instruments

  • NCT02178163 · 1,020 participants · NA

    Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07216703

Source: ClinicalTrials.gov NCT07216703, the US trial registry maintained by the National Library of Medicine. NCT07216703 (large enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.